Skip to main content
Premium Trial:

Request an Annual Quote

Somalogic Closes $200M Financing Round

NEW YORK (GenomeWeb) – Somalogic said today it has closed a $200 million financing round.

The round was led by Chinese healthcare firm iCarbonX whose $161 million equity investment in Somalogic was announced last year. Nan Fung Life Sciences and Madryn Asset Management also invested in the round.

When the iCarbonX investment was announced, Somalogic noted it was shifting its commercial focus to the development of consumer wellness and diagnostics products. It reaffirmed the shift this week, saying in a statement that it plans to use the new financing to pursue its goal of becoming a "leading provider of precision digital health insights."

At the core of the company's strategy is its SomaScan platform, which consists of an array of its Somamer affinity reagents, and can measure up to 5,000 proteins in a single sample.

"We believe SomaLogic’s proteomics technology provides the basis for unique and differentiated insights into human health and disease, with broad implications for diagnosis and treatment," Avinash Amin, managing partner at Madryn Asset Management, said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.